Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study - Scorecard - MDSpire

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

  • By

  • Yi Zhang

  • Hu Zhou

  • Shanshan Suo

  • Junling Zhuang

  • Linhua Yang

  • Aili He

  • Qingchi Liu

  • Xin Du

  • Sujun Gao

  • Yarong Li

  • Yan Li

  • Yuqing Chen

  • Wen Wu

  • Huanling Zhu

  • Guangsheng He

  • Mei Hong

  • Qian Jiang

  • Zhongxing Jiang

  • Hongmei Jing

  • Jishi Wang

  • Na Xu

  • Lingling Yue

  • Cuiping Zheng

  • Zeping Zhou

  • Chenghao Jin

  • Xin Li

  • Lin Liu

  • Yajing Xu

  • Dengshu Wu

  • Feng Zhang

  • Jin Zhang

  • Liqing Wu

  • Hewen Yin

  • Binhua Lv

  • Zhijian Xiao

  • Jie Jin

  • December 18, 2024

  • 0 min

Share

Clinical Scorecard: Comparative Analysis of Gecacitinib and Hydroxyurea in Intermediate-2 or High-Risk Myelofibrosis Patients: Final Results from a Phase 3 Randomized Trial

At a Glance

CategoryDetail
ConditionIntermediate-2 or high-risk myelofibrosis (MF)
Key MechanismsGecacitinib inhibits JAK1, JAK2, JAK3, TYK2, and ACVR1, blocking JAK-STAT signaling and down-regulating hepcidin to improve anemia; Hydroxyurea acts as cytoreductive therapy with variable efficacy
Target PopulationAdult patients (≥18 years) with primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF classified as intermediate-2 or high risk by DIPSS
Care SettingMulticenter clinical trial settings in China; applicable to hematology oncology outpatient and inpatient care

Key Highlights

  • Gecacitinib demonstrated superior spleen size reduction compared to hydroxyurea with favorable safety and tolerability in JAK inhibitor-naïve intermediate- to high-risk MF patients
  • Anemia incidence is notably higher in Chinese MF patients (67%) compared to Western populations (35%), highlighting the need for anemia-targeted therapies
  • Hydroxyurea shows limited spleen response (~40%) and symptom response (~82%) with efficacy typically lasting about one year and frequent worsening of anemia or cytopenia

Guideline-Based Recommendations

Diagnosis

  • Diagnose MF based on clinical features including splenomegaly, systemic symptoms, and blood counts
  • Use DIPSS to stratify patients into intermediate-2 or high-risk categories
  • Exclude patients with prior splenectomy, recent spleen radiation, or significant comorbidities

Management

  • Consider JAK inhibitors for symptom and splenomegaly management; ruxolitinib is approved in China but with lower efficacy and higher dose reductions due to adverse events
  • Gecacitinib offers a novel treatment option targeting JAK and ACVR1 pathways, potentially improving anemia and reducing transfusion dependency
  • Hydroxyurea remains widely used but has limited and variable efficacy with risk of cytopenias

Monitoring & Follow-up

  • Monitor spleen size reduction using imaging and physical examination regularly (e.g., at week 24)
  • Assess blood counts frequently to detect anemia and thrombocytopenia
  • Evaluate treatment-related adverse events to guide dose adjustments or discontinuation

Risks

  • Treatment-related anemia and thrombocytopenia are common with JAK inhibitors, often requiring dose reduction or interruption
  • Hydroxyurea may worsen anemia or cytopenia in nearly 50% of patients within one year
  • Careful patient selection and monitoring are essential to mitigate risks

Patient & Prescribing Data

JAK inhibitor-naïve adult patients with intermediate-2 or high-risk MF, including primary and secondary MF subtypes

Gecacitinib at 100 mg BID showed superior spleen volume reduction and improved anemia parameters compared to hydroxyurea 500 mg BID, with better safety and tolerability profiles

Clinical Best Practices

  • Discontinue prior JAK inhibitor or hydroxyurea therapy at least two weeks before initiating new treatment
  • Stratify patients by DIPSS risk level to guide treatment decisions
  • Use blinded, randomized controlled trial designs to objectively assess efficacy and safety
  • Consider switching to open-label gecacitinib upon spleen-related progression during hydroxyurea treatment
  • Regularly assess spleen size and symptom burden to evaluate treatment response

References

Original Source(s)

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

  • by Yi Zhang, Hu Zhou, Shanshan Suo, Junling Zhuang, Linhua Yang, Aili He, Qingchi Liu, Xin Du, Sujun Gao, Yarong Li, Yan Li, Yuqing Chen, Wen Wu, Huanling Zhu, Guangsheng He, Mei Hong, Qian Jiang, Zhongxing Jiang, Hongmei Jing, Jishi Wang, Na Xu, Lingling Yue, Cuiping Zheng, Zeping Zhou, Chenghao Jin, Xin Li, Lin Liu, Yajing Xu, Dengshu Wu, Feng Zhang, Jin Zhang, Liqing Wu, Hewen Yin, Binhua Lv, Zhijian Xiao, Jie Jin

  • December 18, 2024

Related Content

Clinical Findings in Migrants With Asymptomatic Plasmodium Infections

Smoldering Waldenström macroglobulinemia coexisting with myelodysplastic syndrome: a rare case report and literature review

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.